Alcon ups ante in Novartis scrap; Zenotech shares slump on Daiichi Sankyo court decision

@FierceBiotech: XenoPort's lead program suffers another big setback. Article | Follow @FierceBiotech

@JohnCFierce: Fewer IPOs, smaller VC funds. Lean and mean will be the dominant fashion for Venrock's new, smaller fund. Article | Follow @JohnCFierce

> Alcon's independent directors are upping the ante in their squabble with Novartis. The directors committee (IDC) has now set up a $50 million litigation trust to make sure that minority shareholders get a good deal in selling their shares to the Swiss drugmaker, Reuters reports. Report

> Shares of India's Zenotech Laboratories slumped following a court ruling that Daiichi Sankyo shouldn't be forced to increase its $16.7 million offer for a stake in the biotech. Story

> Optimer Pharmaceuticals has snared a $500,000 milestone payment from Cempra. Report

> Germany's Merck KGaA has gained EU approval to complete its deal to buy the life sciences tool company Millipore. Story

> The FDA has approved Kiadis Pharma's IND app to start the pivotal clinical study for its product ATIR in the United States. Release

> The FDA has provided orphan drug status to Synageva for SBC-102, an enzyme replacement therapy in development to treat Lysosomal Acid Lipase Deficiency. Report

Special Report: Top 10 Pharma CEO salaries of 2009

And Finally... For the fifth time in the past year a woman who had sexual contact with a member of the U.S. military contracted the vaccinia virus after being exposed to the puncture site for a smallpox vaccine. Story